NT-proBNP Response to Heart Failure Therapies An Imperfect Surrogate

被引：18
|
作者：
Cunningham, Jonathan W. [1 ]
Myhre, Peder L. [2 ]
机构：
[1] Brigham & Womens Hosp, Cardiovasc Div, Boston, MA USA
[2] Univ Oslo, Akershus Univ Hosp, Div Med, Oslo, Norway
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2021年 / 78卷 / 13期
关键词：
heart failure; NT-proBNP; prognosis; NATRIURETIC PEPTIDE;
D O I：
10.1016/j.jacc.2021.07.045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1333 / 1336
页数：4
相关论文
共 50 条
  • [41] The Ability of Heart Failure Specialists to Accurately Predict NT-proBNP Levels Based on Clinical Assessment and a Previous NT-proBNP Measurement
    Sedlak, Tara L.
    Chandavimol, Mann
    Calleja, Anna
    Clark, Catherine
    Edmonds, Margaret
    Pu, Aihua
    Humphries, Karin H.
    Ignaszewski, Andrew
    OPEN CARDIOVASCULAR MEDICINE JOURNAL, 2008, 2 : 36 - 40
  • [42] NT-proBNP is a weak indicator of cardiac function and haemodynamic response to exercise in chronic heart failure
    Parovic, Milos
    Okwose, Nduka C.
    Bailey, Kristian
    Velicki, Lazar
    Fras, Zlatko
    Seferovic, Petar M.
    MacGowan, Guy A.
    Jakovljevic, Djordje G.
    ESC HEART FAILURE, 2019, 6 (02): : 449 - 454
  • [43] Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction
    Daubert, Melissa A.
    Yow, Eric
    Barnhart, Huiman X.
    Pina, Ileana L.
    Ahmad, Tariq
    Leifer, Eric
    Cooper, Lawton
    Desvigne-Nickens, Patrice
    Fiuzat, Mona
    Adams, Kirkwood
    Ezekowitz, Justin
    Whellan, David J.
    Januzzi, James L.
    O'Connor, Christopher M.
    Felker, G. Michael
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (10):
  • [44] Variability of NT-proBNP levels in heart failure: implications for clinical application
    Richards, A. Mark
    HEART, 2007, 93 (08) : 899 - 900
  • [45] NT-proBNP levels and hypertension.: Their importance in the diagnosis of heart failure
    Rivera, M
    Talèns-Visconti, R
    Salvador, A
    Bertomeu, V
    Miró, V
    de Burgos, FG
    Climent, V
    Cortés, R
    Payá, R
    Pérez-Boscá, JL
    Mainar, L
    Jordán, A
    Sogorb, F
    Cosín, J
    Mora, V
    Diago, JL
    Marín, F
    REVISTA ESPANOLA DE CARDIOLOGIA, 2004, 57 (05): : 396 - 402
  • [46] Circulating NT-proBNP is glycosylated in severe human heart failure patients
    Hammerer-Lercher, A.
    Halfinger, B.
    Sarg, B.
    Mair, L.
    Puschendorf, B.
    Griesmacher, A.
    Guzman, N. N.
    Lindner, H. H.
    CLINICAL CHEMISTRY, 2007, 53 (06) : A20 - A20
  • [47] DIAGNOSTIC VALUES OF URINE AND PLASMA NT-proBNP IN HEART FAILURE PATIENTS
    Toufan, M.
    Namdar, H.
    Abbasnezhad, M.
    Yaraghi, S.
    CARDIOLOGY, 2013, 125 : 489 - 489
  • [48] Optimizing patient selection in heart failure trials: the role of NT-proBNP
    Savarese, G.
    Orsini, N.
    Hage, C.
    Vedin, O.
    Cosentino, F.
    Rosano, G.
    Dahlstrom, U.
    Lund, L. H.
    EUROPEAN HEART JOURNAL, 2018, 39 : 223 - 223
  • [49] Combining NT-PROBNP and GFR to predict prognosis in patients with heart failure:: An analysis from the international collaborative of NT-proBNP (ICON) study
    van Kimmenade, RR
    Januzzi, JL
    Lainchbury, JG
    Bayes-Genis, A
    Santalo, M
    Ordoñez, J
    Richards, MA
    Pinto, YM
    CIRCULATION, 2005, 112 (17) : U819 - U819
  • [50] Heart Failure: Therapy Control after NT-ProBNP without Benefit
    Kessing, Richard
    AKTUELLE KARDIOLOGIE, 2019, 8 (01)
12345